Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer

NCT03065621 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT03065621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03065621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer
Lead sponsor
Jules Bordet Institute
Phase
Phase 2
Overall status
Completed
Start date
July 5, 2017
Completion date
February 1, 2023
Enrollment
100 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female